News - Abzena

Filter by year

Filter by topic

Pre-Close Period Trading Update

Cambridge, UK, 16 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, today announces its unaudited pre-close update for the year ended 31 March 2018 (‘FY2018’). Following a stronger second half to the year, the Group expects […] Read more

Pre-Close Period Trading Update FY2018

Cambridge, UK, 16 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, today announces its unaudited pre-close update for the year ended 31 March 2018 (‘FY2018’). Following a stronger second half to the year, the Group expects to […] Read more

Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite

CAMBRIDGE, England & BRISTOL, PA, USA, Abzena plc, the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of the facility remodelling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, Pennsylvania site. The facility is being equipped with state-of-the-art […] Read more

Abzena strengthens specialized bioassay offering through access agreement with major cell line depository

Cambridge, UK, 13 March 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository. The agreement with an unnamed institution will allow Abzena access to […] Read more

Abzena takes on new facilities in Cambridge, UK and San Diego

Cambridge, UK 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities. In Cambridge, UK, the Group’s lease has commenced for 30,000 square feet of space in […] Read more

Babraham Bioscience Technologies “Technology Development Laboratory” (TDL) moves to Abzena

Cambridge, UK, 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited (BBT), the company that manages and develops the Babraham Research Campus, to run and develop the services formerly […] Read more

Abzena selects Sartorius Stedim Biotech to equip their U.S. based development and manufacturing sites in San Diego and Bristol

Goettingen, Germany, January 4, 2018 – Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as their preferred equipment supplier in the U.S. Abzena has selected Sartorius Stedim to equip their integrated CDMO facilities in Bristol, PA, for the development […] Read more

Half year results: Growth strategy progressing

Cambridge, UK, 12 December 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes its half year results for the six months to 30 September 2017. Highlights Investment programme progressing in line with the growth strategy including: Upgrading of […] Read more

Abzena secures ADC manufacturing services contract

Cambridge, UK, 11 December 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (“ADC”) […] Read more

Abzena successfully secures over 25 chemistry and ADC service agreements

Bristol PA, USA, 4 December 2017 – Abzena is pleased to announce that their expert integrated Cambridge, UK and Bristol, PA chemistry teams have secured over 25 chemistry and ADC service agreements in the past 90 days. These service agreements span from complex synthetic organic chemistry, antibody drug conjugate (ADC), conjugation and BioNMR projects and […] Read more

Interested in our services? Get In Touch